RenovoRx (RNXT) Investor presentation summary

Company overview and technology

• Focuses on targeted oncology therapies using the proprietary Trans-Arterial Micro-Perfusion (TAMP) platform and FDA-cleared RenovoCath device for drug delivery.

• TAMP increases drug concentration at the tumor site by ~100x and reduces systemic exposure by 43.5% compared to IV administration, potentially improving efficacy and minimizing side effects.

• RenovoCath is applicable to a broad range of solid tumors, with a multibillion-dollar U.S. market opportunity and global expansion potential.

• Holds 19 issued patents and 14 pending, with protection extending through 2045.

Clinical development and data

• Phase III TIGER-PaC trial in locally advanced pancreatic cancer (LAPC) is nearing enrollment completion, with final data expected mid-to-late 2027.

• Interim analysis showed a 6-month median overall survival benefit and 65% reduction in adverse events for TAMP-delivered gemcitabine versus standard IV therapy.

• TAMP platform is being explored in investigator-initiated studies for additional agents and indications, including KRAS inhibitors and oncolytic viruses.

• Registry and post-marketing studies are underway to expand safety and performance data and support label expansion.

Commercialization and financials

• Generated $1.1M in 2025 revenue without a dedicated sales team; Q1 2026 revenue was $563K, over 50% of FY 2025 revenue.

• Commercial footprint includes 16 active cancer centers, with a pipeline of 48 centers and a target of 36 active sites by year-end 2026.

• Projected 2026 revenue is $3-4M, with commercialization expected to fund operations and clinical trial completion into 2H 2027.

• Completed an oversubscribed $10M private placement in March 2026; cash position of $12.4M as of March 31, 2026.